Abstract
Objective To characterize the nature and prevalence of cognitive disorders in older adults with temporal lobe epilepsy (TLE) and compare their cognitive profiles to non-epileptic patients with mild cognitive impairment (i.e., classic MCI; cMCI).
Methods Seventy-eight older patients with TLE, 77 cMCI, and 69 normal aging controls (NAC), all 55-80 years, completed neuropsychological measures of memory, language, executive function and processing speed. An actuarial neuropsychological method designed to diagnose MCI was applied to individual patients to identify older adults with TLE who met diagnostic criteria for MCI (TLE-MCI). A linear classifier was performed to evaluate how well the diagnostic criteria differentiated patients with TLE-MCI from cMCI. In TLE, the contribution of epilepsy-related and vascular risk factors to cognitive impairment was evaluated using multiple regression.
Results Forty-three TLE patients (60%) met criteria for TLE-MCI, demonstrating marked deficits in both memory and language. A classification model between TLE-MCI and cMCI correctly classified 81.1% (90.6% specificity, 61.3% sensitivity) of the cohort based on neuropsychological scores. Whereas TLE-MCI showed greater deficits in language relative to cMCI, patients with cMCI showed greater rapid forgetting on memory measures. Both epilepsy-related risk factors and the presence of leukoaraiosis on MRI contributed to impairment profiles in TLE-MCI.
Interpretation Approximately 60% of older adults with TLE meet diagnostic criteria for a cognitive disorder associated with aging (i.e., MCI). The TLE-MCI phenotype may be secondary to an accumulation of epilepsy and vascular risk factors, signal the onset of a neurodegenerative disease, or represent a combination of both factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported by NIH/NINDS R01 NS065838 (CRM); T32 MH018399 (EK); F31 NS111883-01 (AR); R01 NS088748 and K02NS070960 (DLD); R01NS111022 and R01 AG027161-11 (BPH); NIH/NINDS R01NS097719 and R01NS035140 (RMB); and the U.S. Department of Veterans Affairs CSR&D Service (CDA-2 1IK2CX001415; ECE). Dr. Herman receives support by grants from Citizens United for Research in Epilepsy. Dr. Drane receives grant/contract funding from Medtronic, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Institutional Review Boards at University of California, San Diego (UCSD), Emory University, Cleveland Clinic, and University of Wisconsin-Madison (UWM). Written informed consent was obtained from all TLE patients at UCSD, Emory, and UWM. At Cleveland Clinic, data were collected as part of an IRB-approved data registry.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Authors have full access to all study data and participant consent forms and take full responsibility for the data, the conduct of the research, the analysis and interpretation of the data, and the right to publish all data.
